Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member, please register here.

If you are a Medicare Advantage or Medicare Supplement member, please register here.

MP 2.04.48

Genetic Testing for Warfarin Dose

Medical Policy    

Original Policy Date

Last Review Status/Date
Reviewed with literature search/12:2014
  Return to Medical Policy Index


Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract.  Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage.  Medical technology is constantly changing, and we reserve the right to review and update our policies periodically. 


Warfarin is administered for preventing and treating thromboembolic events in high-risk individuals; warfarin dosing is a challenging process, due to the narrow therapeutic window, variable response to dosing, and serious bleeding events in 5% or more of patients (depending on definition). Patients are typically given a starting dose of 2 to 5 mg and monitored frequently with dose adjustments until a stable International Normalized Ratio (INR) value (a standardized indicator of clotting time) between 2 and 3 is achieved. During this adjustment period, a patient is at high risk of bleeding.

Stable or maintenance warfarin dose varies among individuals by more than an order of magnitude. Factors influencing stable dose include body mass index, age, interacting drugs, and indication for therapy. In addition, genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase subunit C1 (VKORC1) genes together account for a substantial proportion of inter-individual variability. More recently, a single nucleotide polymorphism (SNP; change in a single base-pair in a DNA sequence) in the CYP4F2 gene has been reported to account for a small proportion of the variability in stable dose; CYP4F2 encodes a protein involved in vitamin K oxidation.

Using the results of CYP2C9 and VKORC1 genetic testing to predict a warfarin starting dose that approximates the individual patient’s likely maintenance dose may benefit patients by decreasing the risk of serious bleeding events and the time to stable INR. Algorithms also have been developed that incorporate not only genetic variation but also other significant patient characteristics and clinical factors to predict the best starting dose.

Regulatory Status

Several tests to help assess warfarin sensitivity by determining presence or absence of the relevant CYP2C9, VKORC1, and CYP4F2 variants have been cleared by the U.S. Food and Drug Administration (FDA) for marketing (see Rationale section). Similar tests also may be available as laboratory-developed tests in laboratories licensed under Clinical Laboratory Improvement Amendments for high-complexity testing. The tests are not all the same in terms of the specific variants and number of variants detected. Generally, such tests are not intended as stand-alone tools to determine optimum drug dosage but should be used along with clinical evaluation and other tools, including the INR, to predict the initial dose that best approximates the maintenance dose for patients.

On August 16, 2007, FDA approved updated labeling for Coumadin®, to include information on genetic testing for gene variants that may help “personalize” the starting dose for each patient and reduce the number of serious bleeding events. The label was updated again on January 22, 2010. With each update, manufacturers of warfarin (generic for Coumadin®) were directed to add similar information to their products’ labels. The 2010 update added information on personalizing initial dose according to genotyping results for CYP2C9 and VKORC1, providing a table of genotypes and suggested initial dose ranges for each. However, suggested starting doses also are provided for when genotyping information is unavailable, indicating that genetic testing is not required. Furthermore, FDA did not include information non genetic variation in the label’s black box warning regarding bleeding risk.


Genotyping to determine cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase subunit C1 (VKORC1) genetic polymorphisms is considered investigational for the purpose of managing the administration and dosing of warfarin, including use in guiding the initial warfarin dose to decrease time to stable INR and reduce the risk of serious bleeding.

Policy Guidelines


Effective for 2012, there are CPT codes that are specific to this testing:

81227: CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *5, *6)

81355: VKORC1 (vitamin K epoxide reductase complex, subunit 1) (e.g., warfarin metabolism), gene analysis, common variants (e.g., -1639/3673)

In November 2009, the Centers for Medicare and Medicaid Services issued a new HCPCS code that they made retroactive to August 3, 2009, to facilitate administration of their new national coverage decision on this testing. The code is:

G9143: Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)

Benefit Application
BlueCard/National Account Issues

State or federal mandates (e.g., FEP) may dictate that all devices approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational, and thus these devices may be assessed only on the basis of their medical necessity.


Test Validation

Validation of genotyping to improve pharmacologic treatment outcomes is a multistep process. In general, important steps in the validation process address the following:

  • Analytic validity: Measures technical performance, ie, whether the test accurately and reproducibly detects the gene markers of interest.
  • Clinical validity: Measures the strength of the associations between the selected genetic markers and dose, therapeutic efficacy, and/or adverse events.
  • Clinical utility: Determines whether the use of genotyping for specific genetic markers to guide prescribing and/or dosing improves patient outcomes such as therapeutic effect, time to effective dose, and/or adverse event rate compared to standard treatment without genotyping.

Literature Review

Warfarin is metabolized by the cytochrome P450 enzymeCYP2C9; genetic variants of CYP2C9 result in enzymes with decreased activity, increased serum warfarin concentration at standard doses, and a higher risk of serious bleeding. Information on cytochrome P450 pharmacogenetics was summarized in a 2004 TEC Assessment(1); application to warfarin dosing and important nongenetic influences are discussed in several publications.(2-5) VKORC1 genetic variants alter the degree of warfarin effect on its molecular target and are associated with differences in maintenance doses.(6-10) CYP2C9 and VKORC1 genetic variation accounts for approximately 55% of the variability in warfarin maintenance dose.(10,11) In 2009, a genome-wide association study identified a single SNP, found in the gene CYP4F2, that also is associated with warfarin dose(12); this association was confirmed in a separate, candidate gene study.(13) Subsequent studies predicted that the CYP4F2 polymorphism explains 2% to 7% of the variability in warfarin dose in models including other genetic and nongenetic factors (13,14) Other factors influencing dose include body mass index, age, interacting drugs, and indication for therapy.

The most recent literature review was performed through October 30, 2014.

Analytic Validity

Genetic testing for CYP2C9 and VKORC1 is available at a number of laboratories that have developed in-house tests; these do not require U.S. Food and Drug Administration (FDA) clearance, and information on analytic validity may not be generally available. Some laboratory-developed assays use commercially available reagents that are individually cleared by the FDA as analyte-specific reagents. Test kits cleared for marketing by FDA include eSensor Warfarin Sensitivity Test (GenMark); Rapid Genotyping Assay (ParagonDx); Verigene Warfarin Metabolism Nucleic Acid Test (Nanosphere); Infiniti 2C9-VKORC1 Multiplex Assay for Warfarin (AutoGenomics); and eQ-PCR LightCycler Warfarin Genotyping Kit (TrimGen) (Table 1). Kit inserts for FDA-cleared test kits summarize the extensive analytic validity data required for FDA clearance. Two studies compared kits with FDA clearance and laboratory-developed assays using commercially available reagents and assay platforms; in each, the authors concluded that the assays provided accurate and rapid genotype information for the most common polymorphisms evaluated. (15, 16) However, a 2009 review noted that due to a lack of standardization, tests may detect as few as 2 CYP2C9 variants or as many as 6. (16) A 2013 review indicated that 7 CYP2C9 alleles are important for warfarin response (CYP2C9*2, *3,*5,*6, *8,*11, and*13), and the frequencies of these vary across ethnic groups.(17) ForVKORC1, several known polymorphisms are in strong linkage disequilibrium with one another; thus haplotypes (a combination of polymorphisms at nearby locations) formed from various combinations can be used to assess status. Whether specific haplotypes can improve predictive value is unknown.(18)

Turnaround times for these assays range from approximately 1.5 to 8 hours, not including sample transportation, processing, and delays due to assay scheduling. It is unknown how soon test results might be needed during the warfarin initiation phase should outcome studies indicate net benefit of testing.

Table 1. FDA-Approved Warfarin Tests(19)

Name of Test

Alleles Tested

Estimated Time to Completion, h

eSensor Warfarin Sensitivity Test (GenMark Dx, Carlsbad, CA) a

CYPC9*2 and *3, VKORC1-1639G/A


Rapid Genotyping Assay (ParagonDx, Morrisville, NC)

CYPC9*2 and *3, VKORC1-1173 C/T

Not reported b

Verigene Warfarin Metabolism Nucleic Acid Test (Nanosphere Inc, Northbrook, IL)

CYPC9*2 and *3, VKORC1-1173C/T

≤ 2

Infiniti 2C9-VKORC1 Multiplex Assay for Warfarin (AutoGenomics Inc, Vista, CA) c

CYP2C9*2 and *3, VKORC1 -1639G/A


eQ-PRC LightCycler Warfarin Genotyping Kit (Trimgen Corp, Sparks Glencoe, MD)

CYP2C9*2 and *3, VKORC1 -1639G/A

≤ 2

a eSensor Warfarin Plus Test offers testing for CYP2C9*2, *3, *5, *6, *11, *14, *15, and *16, VKORC1 -1639G>A, and CYP4F2.

b Langley et al (2009) reported a turnaround time of 1.5 hours for the ParagonDx SmartCycler, which may be a precursor assay.(16)

c The expanded Infiniti CYP450 2C9 assay offers testing for CYP2C9*2, *3, *4, *5, *6 and *11, VKORC1 – 1639G.A and 6 additional VKORC variants.

Section Summary

Currently, 5 genotype assays for reduced function CYPC9 and VKORC1 variants are FDA-approved. Evidence for the analytic validity of these tests is provided in the product labels. Although information on analytic validity of laboratory-developed tests is generally unavailable, 2 studies reported comparable analytic validity of FDA-approved and laboratory-developed tests.

Clinical Validity

A 2008 systematic review, commissioned by the American College of Medical Genetics (ACMG), evaluated CYP2C9 and VKORC1 genetic testing before warfarin dosing and concluded the following(20):

  • Clinical validity: CYP2C9 and VKORC1 genotypes contribute significant and independent information to the stable warfarin dose and, compared to the most common combination, some individuals with other genotype combinations will need more than the usual dose, while others will require less.

Authors of several studies of clinical validity, mainly in Caucasian patients already at maintenance doses evaluated retrospectively, have developed algorithms that incorporate VKORC1 and CYP2C9 genetic variant information, as well as patient characteristics and other clinical information, and have evaluated the extent to which these algorithms predict various outcomes such as maintenance dose, time to stable International Normalized Ratio (INR), time spent in target INR range, and serious bleeding events. These algorithms vary in the nongenetic variables included, and in general, account for up to approximately 60% of warfarin maintenance dose variance.(21-28) CYP4F2 genotyping also was added to a retrospective evaluation of several algorithms that already included CYP2C9 and VKORC1; CYP4F2 polymorphisms, however, added only 4% to the fraction of the variability in stable dose explained by the best performing algorithms.(29) A 2012 systematic review and meta-analysis by Liang et al suggested a more substantial contribution of CYP4F2 genetic variants. Compared with wild-type patients, carriers of CYP4F2 variants required warfarin doses 11% and 21% higher for heterozygous and homozygous patients, respectively (30)

Cohort studies that evaluated algorithm-guided dosing in patients starting warfarin reported that algorithms explained 69% to 79% of the variance in maintenance dose.(31,32) In 2009, the International Warfarin Pharmacogenetics Consortium (IWPC) compared an algorithm based only on clinical variables with one that also included genetic factors in a validation cohort of 1009 subjects treated with warfarin. The pharmacogenetic algorithm was significantly more accurate at predicting an initial dose that was close to the maintenance dose in the 46% of patients who required low (≤21 mg/wk) or high (≥49 mg/wk) warfarin doses.(33) The analysis did not address whether a more precise initial dose of warfarin resulted in improved clinical end points. Avery et al (2011) found that 42% of the variability in maintenance dose on days 4 to 7 was explained by the algorithm and that 40% of maintenance dose variability was explained on days 8 to 15.(34)

Other cohort studies also have evaluated the initiation phase of warfarin treatment, reporting the impact of genetic factors on time to therapeutic INR, time to first supratherapeutic (overcoagulation) INR, time above therapeutic range, etc.(35-37) In 2009, Limdi et al estimated that CYP2C9 and VKORC1 explained 6.3% of the variance in dose change over the first 30 days of therapy.(38) Pautas et al (2010) reported that in elderly patients with multiple comorbidities and polypharmacy who were starting warfarin, individuals with multiple variant alleles were at highest risk for overanticoagulation, with an odds ratio of 12.8 (95% confidence interval [CI], 2.8 to 60.0).(39) Ferder et al (2010) reported that the predictive ability of CYP2C9 and VKORC1 genetic variants in patients from the PREVENT (Prevention of Recurrent Venous Thromboembolism) trial gradually diminished over time, from 43% at day 0 (warfarin initiation) to 12% at day 7, 4% at day 14, and 1% at day 21.(40) Moreau et al (2011) studied 187 elderly patients starting warfarin using a “geriatric dosing-algorithm.”(41) Adding CYP2C9 and VKORC1 genotype variants to the initial dosing model increased the explained variance in maintenance dose from less than 10% to 31%. By day 3, VKORC1 was no longer a significant predictor of maintenance dose; however, CYP2C9 genotype remained a significant predictor. By day 6, neither CYP2C9 nor VKORC1 genotype variants were predictive of maintenance dose. These studies indicate that if genotyping results are clinically useful, it is likely only within the first week or less of beginning warfarin therapy.

Gong et al (2011) conducted a prospective cohort study of patients requiring warfarin therapy for atrial fibrillation or venous thromboembolism using a novel pharmacogenetic warfarin initiation protocol.(42) Practical daily loading doses were prescribed for 2 days and were dependent on VKORC1 and CYP2C9 genotypes and, as necessary, on weight. Maintenance dose was determined in a regression model by combining key patient clinical parameters known to influence warfarin dose requirement with genotype. When VKORC1 and CYP2C9 genotypes were incorporated into warfarin initial dose determinations, they had no additional significant effect on time required to reach the first INR within therapeutic range, on risk of overcoagulation (INR ≥4), or on time to stable anticoagulation.

A 2012 study by Horne et al assessed whether pharmacogenetic algorithms can contribute to dose refinements after INR response to warfarin is known.(43) Based on a population (N=1684) drawn from 3 continents and 16 study sites, an algorithm for determining warfarin dose was derived and included a novel treatment response index, comprising previous warfarin dose and INR measurements. The pharmacogenetic warfarin dose-refinement algorithm explained more variability in dosing (R 2=71.8%) compared with the clinical algorithm (R2=64.8%). In addition to these patients, a prospective external validation cohort (n=43) was recruited to determine the safety and accuracy of the clinical algorithm. The pooled pharmacogenetic algorithm explained 58% to 79% of the variation in therapeutic dose, and the time in therapeutic range during days 11 to 30 was 62%. The new pooled clinical algorithm was significantly more accurate than previously validated algorithms.

A 2012 prospective study (N=344) by Perlstein et al assessed the validity of 3 warfarin-dosing algorithms to predict time in therapeutic range and time to first therapeutic INR in a predominantly Caucasian population.(44) The dosing algorithms were developed sequentially to select both an initial warfarin dose and a titration scheme intended to maximize the likelihood of achieving and maintaining the target INR. Algorithm A determined the initial dosing with a decision tree including both clinical and genetic factors based on best practices in the hospital’s anticoagulation management service and the published literature. Algorithm B was generated from an analysis of warfarin dose, INR, genetic factors, demographic factors, and concomitant drug therapy from a group of 74 patients treated with algorithm A. Algorithm C was an update to algorithm B, with a revision of the half maximal inhibitory concentration for VKORC1 haplotypes. The authors found a significant (p=0.04) progressive improvement in mean percentage time in therapeutic range over the entire study period for algorithm A (58.9%), algorithm B (59.7%), and algorithm C (65.8%). The secondary end point of per-patient percentage of INRs outside of the therapeutic range had a similar statistically significant trend across algorithms (p=0.004) with algorithm A reporting 21.6%, algorithm B, 22.8%, and algorithm C, 16.8%. Time to stable therapeutic anticoagulation decreased significantly across algorithms (p<0.001), but time to first therapeutic INR did not vary significantly among the 3 algorithm subgroups. No differences in rates of adverse events were observed during this study.

Several studies have compared the ability of different algorithms to accurately predict stable warfarin dose.(16,45-48) In general, there does not appear to be consensus for a single algorithm at this time. Rather, it may be necessary to select the algorithm best suited to the treatment population due to differences. (47) For example, not all algorithms include the use of drugs that interact with warfarin; in fact, some studies have excluded patients taking interacting drugs. Hatch et al (2008) applied an algorithm developed in patients not taking interacting drugs and showed that when applied to a small number of patients taking interacting drugs, the proportion of dose variance explained by the algorithm decreased by approximately 10 percentage points.(25)

Several authors have examined associations between CYP2C9 and VKORC1 variants and warfarin dosing requirements in children.(49-51)
Findings are preliminary. Proposed dosing algorithms require evaluation in large, prospective, randomized trials in comparison with current standard-of-care approaches to determine net health benefit.


Several studies have included ethnically diverse populations, but it is unclear whether one or several algorithms are needed to address ethnicity. The algorithm developed by Gage et al (2008) explained 55% of the variance in a Caucasian validation cohort but only 40% of the variation in a small African-American cohort.(23) Schelleman et al (2008) developed separate predictive algorithms for Caucasian and African-American populations, which explained 42% of the variance in Caucasians but only 28% in African-Americans.(22) Wu et al (2008) included several different ethnicities in developing their predictive algorithm, which included an ethnicity variable and overall explained 59% of warfarin dose variation.(24) Limdi et al (2010) reported that the contribution of VKORC1 to dose requirement is higher in whites than in nonwhites but that genotype predicts similar dose requirements across Caucasian, African-American, and Asian populations; genotyping for additional VKORC1 variants (ie, other than 1639 G/A and 1173 C/T, the most commonly tested variants) did not improve dose prediction in any group.(52)

Cavallari et al (2011) tested the performance of published warfarin dosing algorithms derived from non-Hispanic cohorts in the Hispanic population. The combination of the VKORC1 and CYP2C9 genotypes and clinical factors explained 56% of patient variability in warfarin dose. The predicted dose was within 1.0 mg/day of the therapeutic dose for 40% to 50% of patients.(53) Gan et al (2011) studied Asian populations and found that patients from India, compared with Chinese and Malay patients, required a dose of 4.9 mg/d versus 3.5 mg/d and 3.3 mg/d, respectively. The higher warfarin doses correlated with particular VKORC1 genotypes found more commonly in the Indian population.(54)

Perera et al (2011) identified novel genetic markers in VKORC1 and CYP2C9 associated with higher warfarin dosing in African-Americans. A regression model, encompassing both genetic and clinical variables, explained 40% of the variability in warfarin maintenance dose.(55) In 2013, Perera et al reported another novel marker in the CYP2C cluster (on chromosome 10) that was associated with reduced warfarin dosing in African-Americans.(56) The proportion of variability in warfarin maintenance dosing explained by adding this novel marker to the IWPC (International Warfarin Pharmacogenetics Consortium) algorithm increased from 21% to 26%. Ramirez et al (2012) developed a predictive algorithm for calculating dose variation in African-Americans including variants in CYP2C9*6 and CALU (which encodes calumenin, a cofactor in the vitamin K epoxide reductase complex).(57) The authors validated an expanded pharmacogenomic dosing algorithm and compared it to the IWPC algorithm with the algorithms explaining 41% and 29% of variation, respectively. Other studies have identified new genetic variants and/or evaluated clinical-genetic algorithms for warfarin dose in Thai,(58) Egyptian,(59,60) Chinese,(61-63) Japanese,(64) Arabic,(65) Turkish,(66) and Scandinavian(67) populations. In general, genetic factors helped models explain 30% to 54% of the overall variance but were not always statistically significant.

Valentin et al (2012) examined a retrospective cohort of Puerto Rican patients (N=97) to determine the influence of CYP2C9 and VKORC1 polymorphisms on warfarin dose in this population.(68) Blood samples were collected during routine INR testing and underwent HILOmet PhyzioType assay to detect 5 single nucleotide polymorphisms (SNPs) in CYP2C9 and 7 SNPs in VKORC1.(68) Median actual effective warfarin doses were compared across CYP2C9 and VKORC1 carrier status (wild type/noncarriers, single, double, triple and quadruple carriers). Significant differences (p<0.001) in warfarin dose were observed between wild type (5.71 mg/d), single carrier (4.64 mg/d), double carrier (3.43 mg/d), triple carriers (2.36 mg/d) and quadruple carriers (1.86 mg/d). No significant difference in time to target INR was identified between groups (p=0.34). Predicted daily warfarin dose was assessed by comparing IWPC pharmacogenomic-guided algorithm, clinical algorithm, and fixed-dose approach. In the low-dose subgroup, the pharmacogenetic algorithm provided dose estimates that were more accurate, and closer to the actual doses required, than the estimates derived from fixed-dose or clinical algorithm (p<0.001 for both comparisons). No differences were detected among the intermediate-dose patients between algorithms, and in the high-dose subgroup, a marginal difference between pharmacogenetic algorithm and clinical algorithm was found (p<0.042). This study is the first to describe the association between SNPs in CYP2C9 and VKORC1 genes and effective warfarin dose in Puerto Rican patients.

Section Summary

In primarily Caucasian populations, several retrospective and prospective cohort studies have documented that pharmacogenomic algorithms can explain 6% to 79% of the variance in warfarin maintenance dosing. In ethnically diverse populations, such algorithms can explain 40% to 59% of the variance. Accuracy of the algorithms appears to depend on the alleles tested; number of reduced function alleles present; use of interacting drugs; ethnicity; time of warfarin dosing after initiation; and maintenance dose eventually required (high or low). Evidence for the ability of pharmacogenomic algorithms to predict maintenance warfarin dose and to increase time in the therapeutic INR range comes from retrospective and cohort studies and is inconsistent. A single dosing algorithm readily generalizable to a diverse population and prospectively tested in a large, representative validation cohort has not been developed.

Clinical Utility

In 2014, 4 systematic reviews with meta-analyses compared genotype-guided warfarin dosing with other dose selection strategies.(69-72) Meta-analyses used random effects models or fixed effects models when statistical heterogeneity (I2 ) was 0%. Two systematic reviews69,70 included the same 9 randomized controlled trials (RCTs) comparing genotype-guided versus clinically guided warfarin dosing (total N=2812); several RCTs reviewed below(73-77) were included, all of which were rated high quality. Range of follow-up duration was 4 to 24 weeks (median, 12 weeks). Publication bias was not detected.(69) With 1 exception, pooled results from both systematic reviews were consistent: There was no statistical difference between dosing strategies in the percentage of time that the INR was in therapeutic range (=89%), the proportion of INRs that exceeded 4 ( =0%), or thromboembolic events ( =0%). However, Stergiopoulos et al found no difference in major bleeding events (pooled relative risk [RR], 0.60; 95% confidence interval [CI], 0.29 to 1.22; =0%), and Franchini et al found reduced major bleeding events with genotype-guided warfarin dosing (pooled RR=0.48; 95% CI, 0.23 to 0.97; I2 =0%). This inconsistency may be attributed to the exclusion of the EU-PACT trial (reviewed below; N=455) from the Franchini et al systematic review.(70) EU-PACT reported no major bleeding events in either warfarin dosing group.

A 2014 systematic review by Goulding et al reported improved clinical outcomes with genotype-guided ersus other (ie, fixed or clinically guided) warfarin dosing.(71) Literature was reviewed through December 2013; 9 RCTs were included, 7 of which overlapped with the systematic reviews previously described, and 6 of which were rated high or very high quality. Range of follow-up duration was 2 to 12 weeks. Pooled mean difference in the percentage of time within the therapeutic range was 6.67 percentage points (95% CI, 1.34 to 12.00; =80%). However, this meta-analysis included 1 trial that showed benefit of genotype-guided dosing compared with fixed initial warfarin dosing (2.5 mg/d),(78) and excluded 2 trials (described below) that showed no benefit of genotype-guided dosing compared with clinically guided dosing.(74,75) Meta-analysis also showed decreased risk of bleeding or thromboembolic events with genotype-guided dosing (pooled risk ratio, 0.57; 95% CI, 0.33 to 0.99; =60%).

A 2014 systematic review by Liao et al reported increased time in the therapeutic range with genotypeguided dosing compared with fixed initial warfarin dosing (3 RCTs;  =48%) but not compared with clinically guided dosing (2 RCTs; =0%).(72) These authors also found no overall difference between pooled groups in adverse events (major bleeding [defined as a decrease in hemoglobin ≥2 g/dL], clinically relevant non-major bleeding, thromboembolism, myocardial infarction, death from any cause, or other condition requiring emergency medical management; 4 RCTs; =0%) or mortality (3 RCTs; =10%).

The ACMG’s 2008 systematic review of CYP2C9 and VKORC1 genetic testing before warfarin dosing (cited earlier) concluded the following(20):

  • “Clinical utility: The purpose of genetic testing in this clinical scenario is to predict an individual’s likely stable warfarin dose by incorporating demographic, clinical, and genotype data (CYP2C9 and VKORC1), and initiate warfarin at that predicted dose as a way to limit high international Normalized Ratio (INR) values (overanticoagulation) that are associated with an increased risk of serious bleeding events. No large study had at the time shown this to be acceptable or effective. Based on limited clinical data, the number needed to treat to avoid 1 serious bleeding event was estimated to range from 48 to 385.”

Few large, well-designed RCTs to address clinical utility have been published. Such studies would evaluate the net benefit of using genetic factors, or algorithms that include genetic factors, to guide initial dosing compared with empirical initial dosing or dosing guided by clinical factors, such as age and body surface area. Additionally, such trials should address the degree to which INR must continue to be monitored to ensure that physicians do not overly rely on dosing algorithms and monitor patients less frequently, potentially increasing adverse events.

In 2007, Anderson et al reported an RCT comparing algorithm (including genetic variables)-guided initial warfarin dosing (n=101) to empirical dosing (n=99).(73) The primary outcome measure was “per-patient percentage of out-of-range INRs.” Algorithm-predicted doses more accurately approximated maintenance doses, resulting in significantly fewer dose changes, but the primary end point was not achieved  (p=0.47); the secondary outcome of serious adverse events also did not differ between study groups (p=0.71). Study patients were carefully managed by a dedicated anticoagulation service, and patients treated with empirical dosing had better than expected outcomes. The authors speculated that empirical therapy “might be less successful in less closely managed and outpatient-based initiation programs” and that a
larger trial would be needed to demonstrate utility. McMillin et al (2010) conducted a nonrandomized study (N=229) in which a gene-based dosing algorithm was compared with standard dosing in patients receiving warfarin after joint replacement surgery.(79) The primary end point was reduction in the incidence of adverse events, and secondary end points were related to INR; no end point reached statistical significance. Patients in this study also were managed by a dedicated and experienced anticoagulation service team. Results of these studies suggest that larger, community-based studies are needed to determine clinical utility.

In association with Medco, a pharmacy benefits management organization, Epstein et al (2010) conducted a cohort study with historical control in patients initiating warfarin therapy who were invited to participate and receive free genotyping.(80) Hospitalization rates (the primary outcome) during the next 6 months were compared with those of a historical control group of similar patients who had initiated warfarin therapy the previous year. The authors reported that the genotyped cohort had 31% fewer hospitalizations overall compared with controls (adjusted hazard ratio [HR], 0.69; 95% CI, 0.58 to 0.82; p=0.001) and 28% fewer hospitalizations for bleeding or thromboembolism (HR=0.72; 95% CI, 0.53 to 0.97; p=0.029). However, the number of patients who were offered enrollment but declined was omitted from publication, making it impossible to exclude selection bias. A high patient refusal rate could produce a highly selected population, not comparable to unselected historical controls. Additionally, hospitalizations related to bleeding or thromboembolism were reduced by 2.2% in absolute terms, and allcause hospitalizations had a much larger reduction of 7.1%. The latter is more than triple that expected if only due to reductions in hospitalizations from bleeding or thromboembolism by improved warfarin dosing. In the absence of selection bias, changes in warfarin dosing would not be expected to impact hospitalizations for nonhematologic reasons. The question of selection bias could have been avoided in this study if genotyping results had been sent randomly to only half of the physicians caring for patients tested.

In association with the Agency for Healthcare Research and Quality and Third Wave Technologies, Burmester et al (2011) conducted a prospective, blinded, randomized trial to compare 2 warfarin dosing algorithms.(74) One algorithm used relevant genetic polymorphisms and clinical parameters (genetic and clinical arm), and the other used only usual clinical parameters (clinical-only arm). A total of 230 primarily hospitalized patients were enrolled. The model including genotype predicted therapeutic warfarin dose better than the clinical-only model (p<0.001); both models predicted dose better than the standard starting dose of 5 mg/d. However, median percent time in therapeutic INR range was the same (28.6% in each group). Median time to stable therapeutic dose also was similar in both arms (approximately 30 days). INR greater than 4.0 occurred in 35% of patients in the clinical-only arm and in 38% of patients in the genetic clinical arm (p=0.94). Thus, clinical outcomes were similar despite improved prediction with genetic information. Patients in this trial may have had frequent INR measurements and dose adjustments in a hospital setting; results may not reflect those likely to be obtained in an outpatient community setting.

A blinded RCT (CoumaGen-II) by Anderson et al (2012) investigated whether 2 pharmacogenetic-guided (PG) testing algorithms were better than standard empiric warfarin dosing.(81) A parallel control group (n=1866) included patients initiating warfarin treatment during the study period, and for these patients, warfarin dose was determined by physician/health care provider. Same day genotyping of CYP2C9 and VKORC1 was provided to 504 patients (257 randomized to a 1-step arm [IWPC algorithm], 247 randomized to a 3-step arm [modified IWPC algorithm]). Most patients (approximately 92%) were Caucasian. Primary end points were the percentage of out-of-therapeutic range INRs and time in therapeutic INR range during the first month and through the third month of warfarin therapy. Both PG approaches were equivalent at 1 and 3 months for all outcomes with a stable maintenance dose determined in 444 patients (88%). There was an inverse relation between the number of reduced function alleles and stable maintenance dose (p<0.001). Pharmacogenomic guidance was more accurate in wild-type
patients and in those with multiple variants (p<0.001). Both PG arms were pooled and were observed to be superior to the standard dosing approach with significant (p<0.001) reductions in percent of time out of INR range and percent of time in therapeutic range at 1 and 3 months after controlling for relevant variables. Adverse events (hemorrhagic events, thromboembolic events, or other serious adverse events) were greater in the control group (9.4%) compared with the PG group (4.5%), with an adjusted RR of 0.44 (95% CI, 0.28 to 0.70; p<0.001).

Jonas et al (2013) conducted a double-blind RCT in 109 adults who were initiating long-term warfarin therapy.(75) Patients were randomized to warfarin dosing by an algorithm that contained both genetic (specifically, CYP2D6*2 and *3 and VKORC1-1639G>A [also known as VKORC1-3673G>A]) and clinical factors or clinical factors only. Most patients (70%) were Caucasian, and 30% were African-American. Primary efficacy outcomes were the mean number of anticoagulation visits (to clinic or physician) in 90 days and time in the therapeutic range (TTR). The trial was powered to detect a difference of 2 visits and a 10% difference in TTR. There were no statistically significant differences between intervention groups for any primary or secondary outcome. (Secondary outcomes included emergency visits, hospitalizations, minor [not requiring hospitalization or transfusion] and major hemorrhagic events, thrombotic events and deaths, but the trial was not powered to detect differences in these outcomes.) The authors concluded, “Overall, the current evidence from our trial and from previously published trials does not establish clinical utility of genotype-guided warfarin dosing.”

Two larger RCTs of pharmacogenetic dosing algorithms also were published in 2013.(76,77) The larger of these, the Clarification of Optimal Anticoagulation through Genetics (COAG) trial, was conducted in the U.S. by the National Heart, Lung, and Blood Institute,(76) and the smaller trial was conducted in Sweden and England by the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) consortium.(77) In both trials, the intervention period was the first 5 days of dosing; genotyping comprised the CYP2D6*2 and *3 and VKORC1-1639G>A alleles; and the primary outcome was the mean percentage of time in the therapeutic INR range of 2.0 to 3.0. Neither trial reported an intention-to-treat analysis. The COAG trial(76) compared 2 dosing algorithms in 1015 patients who were initiating a minimum 1-month course of warfarin
therapy (58% for deep vein thrombosis or pulmonary embolism, 22% for atrial fibrillation, 11% for other indications). Median patient age was 58 years (interquartile range [IQR], 46-70). Patients were stratified by self-reported race (black [27%] or nonblack [73%]), randomized in double-blind fashion to an algorithm of both clinical and genetic factors or clinical factors only, and followed for 4 weeks. Ninety-four percent of
patients (n=955) completed the 5-day intervention period and were included in efficacy analyses. The between-group difference in the primary outcome was not statistically significant (45.2% vs 45.4% of INRs were in the therapeutic range in the genotype-guided and clinically guided groups, respectively; p=0.91). Among 255 black patients, a statistically significant difference favored the clinically guided group (35.2% vs 43.5% of INRs were in the therapeutic range in the genotype-guided and clinically guided groups, respectively; p=0.01). The principal secondary outcome (a composite of INR ≥4, major bleeding [fatal hemorrhage, intracranial bleeding, or symptomatic bleeding requiring overnight hospitalization, transfusion, angiographic intervention, or surgery], or thromboembolism) occurred in 20% and 21% of the genotype- and clinically guided groups, respectively (p=0.93). Incidences of each component of the composite outcome also were similar between groups, although the trial was not powered for these outcomes.

The EU-PACT trial compared algorithm-based dosing, using clinical and genetic information, with standard fixed-dose warfarin initiation (with a 10-mg loading dose on day 1) in 455 patients with atrial fibrillation (72%) or venous thromboembolism (28%).(77) Almost all patients (99%) were white. Mean patient age was 67.5 years (range, 24-90). Patients were randomized to one of the 2 treatment groups and followed for 12 weeks. Ninety-four percent of patients had 13 or more days of INR data and were included in efficacy analyses. The between-group difference in the primary outcome favored genotype-guided dosing (67.4% vs 60.3% of INRs were in the therapeutic range in the genotype-guided and fixed-dose groups, respectively; p<0.001). The median time to reach a therapeutic INR (a secondary outcome, calculated as the median time to the first of 2 target INR values, measured at least 1 week apart) was 21 days (IQR, 8-36) in the genotype-guided group and 29 days (IQR, 14-58) in the fixed-dose group (p<0.001); the percentage of TTR was no longer statistically different between groups after week 8.

Excessive anticoagulation (INR ≥4.0) occurred in fewer patients in the genotype-guided group (27%) than in the control group (37%; p=0.03). Bleeding events occurred in approximately 38% of patients in each group, and most consisted of bruising and nosebleeds. One thromboembolic event occurred in the control group.

Section Summary

Randomized trials and meta-analyses of these trials have examined the use of pharmacogenomic algorithms to guide initial warfarin dosing and yielded inconsistent results. Several trials showed improved ability to predict maintenance dose when genetic information was added to clinical algorithms. However, effects on INR or clinical outcomes were not always statistically significant. The ability of pharmacogenomic algorithms to improve these outcomes and net health benefit compared with current clinical data monitoring approaches has not been demonstrated.

Ongoing and Unpublished Clinical Trials

Several large clinical trials, including some randomized, comparative clinical trials, designed to address clinical utility, are currently in progress(82) and are summarized next:

  • Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INITIATION (WARFARIN) Trial conducted by Iverson Genetic Diagnostics, Inc. (NCT01305148). The trial will determine if the use of genetic information can predict warfarin dosing that will result in fewer
    hospitalizations and deaths related to warfarin. Setting: 16 hospitals/research centers in 7 states. Targeted enrollment: 4300 participants. Currently recruiting (additional information online at: 
  • Clinical and Economic Implications of Genetic Testing for Warfarin Management trial conducted by the University of Chicago, in collaboration with AHRQ (NCT00964353). The trial will determine clinical outcomes and costs associated with the use of genotype-guided warfarin dose algorithms compared with current standards of care. Setting: University medical center. Targeted enrollment: 268 participants. Currently active, not recruiting.
  • Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT Trial conducted by the Washington University School of Medicine, in collaboration with Intermountain Health Care, University of Utah, Hospital for Special Surgery, New York, and National Heart, Lung, and Blood Institute
    (NCT01006733). The trial will develop strategies to improve the safety and effectiveness of clot prevention by customizing anticoagulants to individual genetic and clinical profiles. Setting: 4 hospital/university medical centers. Targeted enrollment: 1600 participants. Currently recruiting. Estimated completion: August 2015. The trial design was published by Lenzini et al.(27)
  • Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach Trial conducted by the University of Puerto Rico, in collaboration with National Heart, Lung, and Blood Institute, Hartford Hospital, and VA Caribbean Healthcare System (NCT01318057). The trial will determine the variants of CYP2C9 and VKORC1 alleles associated with warfarin treatment clinical responses in order to develop a better method of dose estimation in Puerto Ricans. Setting: hospital. Targeted enrollment: 350 participants. Currently recruiting.
  • Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regimen for Calculating Warfarin Maintenance Dose conducted by the National University Hospital in Singapore (NCT00700895). The trial will randomize patients with an indication for warfarin therapy to genetics-guided dosing or traditional trial and error dosing with protocol guided-adjustments. The primary outcome is the number of dosage adjustments required to achieve the target INR at 1, 2, and 3 months. Setting: 2 university medical centers. Targeted enrollment: 320 participants. Currently recruiting.
  • A Trial of Genotype-based Warfarin Initiation in Patients With Mechanical Prosthetic Heart Valve (SYSU-WARFA) conducted by Sun Yat-Sen University Hospital in China (NCT01633957). The trial will randomize patients who have undergone elective mitral and/or aortic mechanical valve replacement to warfarin dosing based on genotype or based on clinical factors. Primary outcomes are time to steady dosing and time in therapeutic warfarin dose range. Secondary outcomes include mortality, bleeding, and thrombosis. Setting: a single university medical center. Targeted enrollment: 200. Currently recruiting.

Summary of Evidence

Although the evidence supports a strong association between genetic variants and stable warfarin dose, and to a lesser extent, between genetic variants and International Normalized Ratio (INR) and bleeding outcomes, the evidence is not sufficient to conclude that testing for CYP2C9 and VKORC1 (and possibly CYP4F2) genetic variants improves health outcomes. Genetic testing may help predict the initial warfarin
dose within the first week of warfarin treatment, but the evidence, including several meta-analyses of randomized controlled trials, does not provide consistent evidence for the conclusion that clinically relevant outcomes, such as bleeding rates or thromboembolism, are improved. Therefore, genotyping for variants to predict initial warfarin dose is considered investigational.

Practice Guidelines and Position Statements

The 2008 American College of Medical Genetics policy statement concluded: "There is insufficient evidence, at this time, to recommend for or against routine CYP2C9 and VKORC1 testing in warfarinnaive patients."(83)

The 9th edition of the American College of Chest Physicians evidence-based clinical practice guidelines on Antithrombotic Therapy and Prevention of Thrombosis, published in 2012, states, “For patients initiating VKA [vitamin K antagonist] therapy, we recommend against the routine use of pharmacogenetic testing for guiding doses of VKA (Grade 1B).”(84)

In 2011, the 3rd European Science Foundation–University of Barcelona Conference in Biomedicine on Pharmacogenetics and Pharmacogenomics published a summary on CYP2C9 and VKORCI genotyping for warfarin dosing. The report noted the Food and Drug Administration’s addition of genetic information to the warfarin label but stated that the European Medicines Agency has not yet decided whether to include this information in European drug labels.(85)

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force has not addressed genotype-guided warfarin therapy.

Medicare National Coverage

On August 3, 2009, the Centers for Medicare and Medicaid Services (CMS) published a National Coverage Analysis (available online at: regarding pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin response. CMS states that “the available evidence does not demonstrate that [such testing] improves health outcomes” in Medicare beneficiaries and that “pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness is not reasonable and necessary under §1862(a)(1)(A) of the Social Security Act. However, we do believe the available evidence supports that Coverage with Evidence Development under §1862(a)(1)(E) of the Social Security Act is appropriate.”

CMS now covers pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin response only when provided to Medicare beneficiaries who are candidates for anticoagulation therapy with warfarin and who:

  1. Have not been previously tested for CYP2C9 or VKORC1 alleles; and
  2. Have received fewer than five days of warfarin in the anticoagulation regimen for which the testing is ordered; and
  3. Are enrolled in a prospective, randomized, controlled clinical study when that study meets described standards.


  1. Blue Cross and Blue Shield Association. Technology Evaluation Center (TEC). TEC Special Report: Genotyping for Cytochrome P450 Polymorphisms to Determine Drug-metabolizer Status. TEC Assessments 2004; Volume 19, Tab 9.
  2. Wadelius M, Sorlin K, Wallerman O et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004; 4(1):40-48. PMID 14676821
  3. Gage BF, Eby C, Milligan PE et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91(1):87-94. PMID 14691573
  4. Hillman MA, Wilke RA, Caldwell MD et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 14(8):539-47. PMID 15284536
  5. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009; 30(7):375-86. PMID 19540002
  6. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22):2285-93. PMID 15930419
  7. Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet July 2005; 14(13):1745-51. PMID 15888487
  8. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and interethnical variability of oral anticoagulation. Thromb Haemost. Oct 2005;94(4):773-779. PMID 16270629
  9. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. Jan 15 2005;105(2):645-649. PMID 15358623
  10. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262-270. PMID 15883587
  11. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. Oct 1 2005;106(7):2329-2333. PMID 15947090
  12. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. Mar 2009;5(3):e1000433. PMID 19300499
  13. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. Apr 15 2008;111(8):4106-4112. PMID 18250228
  14. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. Feb 2009;10(2):261-266. PMID 19207028
  15. King CR, Porche-Sorbet RM, Gage BF, et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol. Jun 2008;129(6):876-883. PMID 18480003
  16. Langley MR, Booker JK, Evans JP, et al. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn. May 2009;11(3):216-225. PMID 19324988
  17. Daly A. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch Toxicol. 2013/03/01 2013;87(3):407-420.
  18. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med. Aug 18 2009;151(4):270-273, W295. PMID 19687493
  19. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. Dec 2011;31(12):1192-1207. PMID 22122181
  20. McClain MR, Palomaki GE, Piper M, et al. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. Feb 2008;10(2):89-98. PMID 18281915
  21. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. Jul 2007;53(7):1199-1205. PMID 17510308
  22. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther. Sep 2008;84(3):332-339. PMID 18596683
  23. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. Sep 2008;84(3):326-331. PMID 18305455
  24. Wu AH, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. Feb 2008;9(2):169-178. PMID 18370846
  25. Hatch E, Wynne H, Avery P, et al. Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients. J Thromb Haemost. Jun 2008;6(6):1038-1040. PMID 18419746
  26. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. Mar 2007;121(1):23-34. PMID 17048007
  27. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. May 2010;87(5):572-578. PMID 20375999
  28. Wells PS, Majeed H, Kassem S, et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res. Jun 2010;125(6):e259-264. PMID 20421126
  29. Sagreiya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics. Jul 2010;20(7):407-413. PMID 20442691
  30. Liang R, Wang C, Zhao H, et al. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res. Jul 2012;130(1):38-44. PMID 22192158
  31. Wen MS, Lee M, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. Jul 2008;84(1):83-89. PMID 18183038
  32. Millican EA, Lenzini PA, Milligan PE, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. Sep 1 2007;110(5):1511-1515. PMID 17387222
  33. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. Feb 19 2009;360(8):753-764. PMID 19228618
  34. Avery PJ, Jorgensen A, Hamberg AK, et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther. Nov 2011;90(5):701-706. PMID 22012312
  35. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. Mar 6 2008;358(10):999-1008. PMID 18322281
  36. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. Jan 22 2009;113(4):784-792. PMID 18574025
  37. Meckley LM, Wittkowsky AK, Rieder MJ, et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost. Aug 2008;100(2):229-239. PMID 18690342
  38. Limdi NA, Wiener H, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis. Jul-Aug 2009;43(1):119-128. PMID 19297219
  39. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. Jan 2010;87(1):57-64. PMID 19794411
  40. Ferder NS, Eby CS, Deych E, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. Jan 2010;8(1):95-100. PMID 19874474
  41. Moreau C, Pautas E, Gouin-Thibault I, et al. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost. Apr 2011;9(4):711-718. PMID 21255252
  42. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood. Jul 1 2011. PMID 21725053
  43. Horne BD, Lenzini PA, Wadelius M, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost. Feb 2012;107(2):232-240. PMID 22186998
  44. Perlstein TS, Goldhaber SZ, Nelson K, et al. The Creating an Optimal Warfarin Nomogram (CROWN) Study. Thromb Haemost. Jan 2012;107(1):59-68. PMID 22116191
  45. Shaw PB, Donovan JL, Tran MT, et al. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis. Aug 2010;30(2):220-225. PMID 20204461
  46. Lubitz SA, Scott SA, Rothlauf EB, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost. May 2010;8(5):1018-1026. PMID 20128861
  47. Roper N, Storer B, Bona R, et al. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn. May 2010;12(3):283-291. PMID 20228265
  48. Zambon CF, Pengo V, Padrini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics. Jan 2011;12(1):15-25. PMID 21174619
  49. Hamberg AK, Wadelius M. Pharmacogenetics-based warfarin dosing in children. Pharmacogenomics. Feb 2014;15(3):361-374. PMID 24533715
  50. Hawcutt DB, Ghani AA, Sutton L, et al. Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenomics J. Jul 8 2014. PMID 25001883
  51. Vear SI, Ayers GD, Van Driest SL, et al. The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. Br J Haematol. Jun 2014;165(6):832-835. PMID 24601977
  52. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. May 6 2010;115(18):3827-3834. PMID 20203262
  53. Cavallari LH, Momary KM, Patel SR, et al. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis. Feb 15 2011;46(2):147-150. PMID 21185752
  54. Gan GG, Phipps ME, Lee MM, et al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol. Jun 2011;90(6):635-641. PMID 21110192
  55. Perera MA, Gamazon E, Cavallari LH, et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther. Mar 2011;89(3):408-415. PMID 21270790
  56. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. Aug 31 2013;382(9894):790-796. PMID 23755828
  57. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African- Americans using DNA samples linked to an electronic health record. Pharmacogenomics. Mar 2012;13(4):407-418. PMID 22329724
  58. Sangviroon A, Panomvana D, Tassaneeyakul W, et al. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab Pharmacokinet. 2010;25(6):531-538. PMID 20930419
  59. Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. Mar 2011;21(3):130-135. PMID 21228733
  60. Bazan NS, Sabry NA, Rizk A, et al. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. Int J Clin Pharm. Dec 2012;34(6):837-844. PMID 22851439
  61. You JH, Wong RS, Waye MM, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis. Jan 2011;31(1):113-118. PMID 20585834
  62. Ma C, Zhang Y, Xu Q, et al. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Int J Hematol. Dec 2012;96(6):719-728. PMID 23104259
  63. Xu Q, Xu B, Zhang Y, et al. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. Thromb Haemost. Dec 2012;108(6):1132-1140. PMID 23015069
  64. Aomori T, Obayashi K, Fujita Y, et al. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose. Pharmazie. Mar 2011;66(3):222-225. PMID 21553655
  65. Alzahrani AM, Ragia G, Hanieh H, et al. Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. Biomed Res Int. 2013;2013:315980. PMID 23586031
  66. Ozer M, Demirci Y, Hizel C, et al. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Basic Clin Pharmacol Toxicol. Mar 2013;112(3):209-214. PMID 23061746
  67. Skov J, Bladbjerg EM, Leppin A, et al. The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thromb Res. Feb 2013;131(2):125-129. PMID 23159229
  68. Valentin, II, Vazquez J, Rivera-Miranda G, et al. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. Feb 2012;46(2):208-218. PMID 22274142
  69. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. Aug 2014;174(8):1330-1338. PMID 24935087
  70. Franchini M, Mengoli C, Cruciani M, et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost. Sep 2014;12(9):1480-1487. PMID 25040440
  71. Goulding R, Dawes D, Price M, et al. Genotype-guided Drug Prescribing: A Systematic Review and Metaanalysis of Randomized Control Trials. Br J Clin Pharmacol. Jul 24 2014. PMID 25060532
  72. Liao Z, Feng S, Ling P, et al. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. J Thromb Thrombolysis. Jun 25 2014. PMID 24962733
  73. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. Nov 27 2007;116(22):2563-2570. PMID 17989110
  74. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med. Jun 2011;13(6):509-518. PMID 21423021
  75. Jonas DE, Evans JP, McLeod HL, et al. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 2013/10/01 2013;14(13):1593-1603. PMID
  76. Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. Dec 12 2013;369(24):2283-2293. PMID 24251361
  77. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. Dec 12 2013;369(24):2294-2303. PMID 24251363
  78. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. Mar 2009;19(3):226-234. PMID 19177029
  79. McMillin GA, Melis R, Wilson A, et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit. Jun 2010;32(3):338-345.PMID 20386359
  80. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. Jun 22 2010;55(25):2804-2812. PMID 20381283
  81. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. Apr 24 2012;125(16):1997-2005. PMID 22431865
  82. Kangelaris KN, Bent S, Nussbaum RL, et al. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. May 2009;24(5):656-664. PMID 19306050
  83. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. Feb 2008;10(2):139-150. PMID 18281922
  84. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. Feb 2012;141(2 Suppl):7S-47S. PMID 22315257
  85. Becquemont L, Alfirevic A, Amstutz U, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. Jan 2011;12(1):113-124. PMID 21174626







CPT   See Policy Guidelines section
ICD-9 Diagnosis   Investigational for all codes
HCPCS G9143 Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)
ICD-10-CM (effective 10/1/15)   Investigational for all relevant diagnoses
  I48.0 Atrial fibrillation
  Z86.71 Personal history of venous thrombosis and embolism
  Z86.72 Personal history of thrombophlebitis
ICD-10-PCS (effective 10/1/15)   Not applicable. ICD-10-PCS codes are only used for inpatient services. There are no ICD procedure codes for laboratory tests.



Cytochrome p450
Vitamin K epoxide reductase subunit C1
Pharmacogenomic Testing

Policy History 


Date Action Reason
09/18/07 Add policy to Medicine section, Pathology, Laboratory subsection New policy
11/13/08 Replace policy Policy updated following literature review. Reference numbers 11, 13 to 23, 25, 26, and 29 added; remaining references renumbered. Policy statement unchanged 
12/03/09 Replace policy Policy updated following literature review. Reference numbers 5, 12–14, 16, 17, 28, 29, 32, 35–38 added; remaining references renumbered. Policy statement unchanged
12/09/10 Replace policy Policy updated with literature review; no changes to policy statements. References 25, 26, 34-38, 40, 41, added; reference 31 updatedPolicy updated with literature review; no changes to policy statements. References 25, 26, 34-38, 40, 41, added; reference 31 updated
12/08/11 Replace policy Policy updated with literature review; no changes to policy statements. References 33, 38, 44-46, 53, 58, 60 added.
1/10/13 Replacy Policy-correction only Revised the following sentence in the Rationale section discussion of reference 29 to add the missing word “higher” – Compared with wild type patients, carriers of CYP4F2 variants required warfarin doses 11% and 21% higher for heterozygous and homozygous patients, respectively.
12/12/13 Replace policy Policy updated with literature review through November 14, 2013; no changes to policy statement. References 17, 53, 57, 59-60, 62-64, and 71-73 added; references renumbered.
12/11/14 Replace policy Policy updated with literature review through October 30, 2014; references 49-51, 69-72, and 78 added; policy statement unchanged.


Resource Center

Find a Provider Find a Pharmacy Medicare Medicare Formulary